BioMarin PharmaceuticalsBMRN
Recorded

BioMarin Pharmaceuticals UBS Global Biopharma Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Johnny LeeAnalyst

All right. We'll get started. Thank you for joining our UBS Global Biopharma Conference. My name is Jun Li, one of the biotech analysts at UBS. Here to kick us off is Alexander Hardy, CEO of BioMarin, and Brian, the CFO of BioMarin. Alexander, thank you so much for spending time with us this morning. For the audience who may be new to the story, tell us who BioMarin is today. What have you delivered over the last three years since you joined? Why did you join? Why should investors be excited about what's ahead?

Alexander HardyCEO

Well, Jun, thanks very much for having us, and thanks, everybody, for joining for this conversation. That's a lot of questions, but let me just, I suppose, start off with, where are we in our journey? I've been at BioMarin for three years. We've done a lot of stuff during that time. I came to BioMarin because I saw the potential to create an iconic biotech company focused on rare diseases. There are also other large biotech companies, but they are not focused on rare diseases, and there are also mid-size rare disease companies, but they're part of larger enterprises. I saw all the building blocks, and I am convinced that we're on the path to do that. The company, over 25 years, has built a set of capabilities all the way through from research, development, regulatory, manufacturing, commercialization, focused on rare diseases.

Alexander HardyCEO

An 80-country footprint, which is really amazing, and that's what you need if you're in rare diseases, because you have to go to where the prevalent patient populations are. In many cases, in many of these diseases, the largest patient potential is outside Europe and the U.S., and we have that capability to reach them. We now have nine products. Six of them are first-in-disease treatments. I mean, nine products is really an incredible base. What we've been doing over the last three years is really getting the company operating at scale to create that leadership position. We've dramatically improved the financial performance of the company. Since 2023, we've increased revenue by 60%. Between 2023 and 2025, we've increased earnings per share, doubled it, and cash flow by five times.

Alexander HardyCEO

That financial strength has allowed us to really build a really compelling balance sheet, and we've done a lot of transactions. We got GALAFOLD and POMBILITI and OPFOLDA from the Amicus acquisition. In addition, we've done four other pipeline deals that have given us assets all the way through from phase III to phase II to early research. We're now at the stage, we're in 2027, where we start to see a bunch of really exciting clinical catalysts. We have BMN 333, our long-acting CNP. We have first patient data next year. No doubt we're going to talk about that. We have BMN 440 for HPP. We have the first patient data for that. That's a very, very large potential drug.

Alexander HardyCEO

And then we have, in front of the FDA, we have potentially our seventh first-in-disease treatment, which is Voxzogo for hypochondroplasia, with a PDUFA date in May. You can see that we've got a fully formed, at-scale rare disease company here, and we've got an exciting growth trajectory, strong financial performance, and now an exciting pipeline as well.

Alexander HardyCEO

Excellent. Thanks for- I think I answered all your questions.

Johnny LeeAnalyst

I could be wrong. We'll dig into it.

Johnny LeeAnalyst

Okay, good. Let's go to the three Ds.

Johnny LeeAnalyst

We'll start with GALAFOLD and POMBILITI. 3Q was the first full quarter since you acquired Amicus Therapeutics, and both products are performing well. What gets each product to the peak revenues that you laid out in August?

Alexander HardyCEO

Yeah. Shall I go ahead? I'll go ahead. We set out, the Amicus Therapeutics acquisition was really a compelling acquisition. Basically, Amicus Therapeutics was a smaller-scale version of BioMarin, but we had more scale, more capabilities, and the ability to really maximize these two assets, GALAFOLD and POMBILITI and OPFOLDA. We have communicated in the second quarter earnings, we communicated what, in our hands, we believe the potential of these products could be. GALAFOLD, we believe we can achieve a peak sales of $1.4 billion.

Alexander HardyCEO

POMBILITI and OPFOLDA, $1.2 billion. That's because we have that global footprint at a greater scale than Amicus Therapeutics had, and we have a depth of capabilities and the ability to invest to be able to achieve a faster peak and a faster ramp and a higher peak. With GALAFOLD, we believe the opportunity is particularly on the diagnosis side.

Alexander HardyCEO

There are a lot of patients with the disease of Fabry that are not diagnosed. We think treatment rates can also be increased. We think GALAFOLD is very well positioned there. In the third quarter, we just announced a 13% increase in number of patients treated, which was the first quarter in our hands versus a prior year under Amicus control. That's a really nice level of growth.

Alexander HardyCEO

We're also going to, of course, expand the number of countries as well. We're planning to launch in another 10 countries. Right now, that's our plans. Then POMBILITI and OPFOLDA, the opportunity there really is increasing the switch rate.

Alexander HardyCEO

It's well-positioned there with the evidence, the differentiation. We just, in October, released the PROPEL data, which is the five-year data.

Alexander HardyCEO

All really shows the benefits of switching from the existing ERTs to POMBILITI and OPFOLDA. We grew patients on therapy in the third quarter by 69%. I think you can already see that we're on a different trajectory, and we're confident in our ability to achieve those higher peak sales. That translates to about 40% higher peak for GALAFOLD and 20% higher peak in POMBILITI and OPFOLDA than Amicus would have achieved.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day